SEARCH

SEARCH BY CITATION

References

  • 1
    Lok AS, McMahon B. AASLD practice guidelines. Chronic hepatitis B. Hepatology 2001; 34: 122541.
  • 2
    Funk ML, Rosemberg DM, Lok AS. World-wide epidemiology of HBeg – negative chronic hepatitis B and associated precore and core promoter variants. J Viral Hepat 2002; 9: 5261.
  • 3
    Ballard AL, Boxall EH. Epidemiology of precore mutants of hepatitis B in the United Kingdom. J Med Virol 2000; 62: 46370.
  • 4
    Hadziyannis SJ. Hepatitis B e antigen negative chronic hepatitis B: from clinical recognition to pathogenesis and treatment. Vir Hep Rev 1995; 1: 736.
  • 5
    Hadziyannis SJ, Vassilopoulos D. Hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2001; 34: 61724.
  • 6
    Lai CL, Chien RN, Leung NW, et al. A one year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 1998; 339: 61.
  • 7
    Dienstag JL, Schiff ER, Wright TR, et al. Lamivudine as initial treatment for chronic hepatitis B in the US. N Engl J Med 1999; 341: 1256.
  • 8
    Tassopoulos NC, Volpes R, Pastore G, et al. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Hepatology 1999; 29: 88996.
  • 9
    Liaw YF, Leung NW, Chang TT, et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Gastroenterology 2000; 119: 17280.
  • 10
    Guan R, Lai CL, Liaw YF, Lim SG, Lee CM. Efficacy and safety of 5-years lamivudine treatment of Chinese patients with chronic hepatitis B. (abstract). J Gastroenterol Hepatol 2001; 16 (Suppl. 1): A60.
  • 11
    Hadziyannis SJ, Papatheodoridis GV, Dimou E, Laras A, Papaioannou C. Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen – negative chronic hepatitis B. Hepatology 2000; 32: 84751.
  • 12
    Lok AS, Hussain M, Cursano C, et al. Evolution of hepatitis B virus e antigen – negative patients receiving lamivudine therapy. Hepatology 2000; 32: 114553.
  • 13
    Papatheodoridis GV, Dimou E, Laras A, Papadimitropoulos V, Hadziyannis SJ. Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease. Hepatology 2002; 36: 21926.
  • 14
    Manolakopoulos S, Karatapanis S, Elefsiniotis J, et al. Clinical course of lamivudine monotherapy in patients with decompensated cirrhosis due to HBeAg-negative chronic hepatitis B. Am J Gastroenterol 2004; 99: 5763.
    Direct Link:
  • 15
    Hadziyannis S, Tassopoulos N, Heathcote E, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003; 348: 8007.
  • 16
    Marcellin P, Chang TT, Lim SG, et al. Adefovir-dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003; 348: 80816.
  • 17
    Perrillo R, Hann HW, Mutimer D, et al. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology 2004; 1: 8190.
  • 18
    Peters M, Hann HW, Martin P, et al. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 2004; 126: 91101.
  • 19
    Consigny Y, Plessier A, Martinox M, et al. Predictors of a pejorative outcome in patients treated with adefovir dipivoxil for reactivation of chronic hepatitis B due to lamivudine-resistant hepatitis B virus mutant. J Hepatol 2004; 42 (Suppl. 2): 173.
  • 20
    Kessler HH, Pierer K, Dragon E, et al. Evaluation of a new assay for HBV DNA quantitation in patients with chronic hepatitis B. Clin Diagn Virol 1998; 9: 3743.
  • 21
    Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 6969.
  • 22
    Perrillo R, Lai C, Liaw YF, et al. Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. Hepatology 2002; 36: 18694.
  • 23
    Cho S, Hahm KB, Kim JH. Reversion from precore/core promoter mutants to wild-type hepatitis B virus during the course of lamivudine therapy. Hepatology 2000; 32: 11639.
  • 24
    Di Marco V, Marzano A, Lampertico P, et al. Clinical outcome of HbeAg negative chronic hepatitis B in relation to virological response to lamivudine. Hepatology 2004; 40: 88391.
  • 25
    Lok ASF, Lai CL, Leung N, et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003; 125: 171422.
  • 26
    Papatheodoridis GV, Dimou E, Dimakopoulos K, et al. Long-term outcome of patients with HBeAg – negative chronic hepatitis B under nucleos(t)ide analogues maintenance therapy starting with lamivudine. Hepatology 2005; 42: 1219.
  • 27
    Germanidis G, Roudot-Thoraval F, Guerre F, et al. Clinical significance of hepatitis B virus DNA levels in HBeAg-negative, HBV genotype D-infected patients. Hepatology 2004; 40: 675A.
  • 28
    Gaia S, Marzano A, Smedile A, et al. Four years of treatment with lamivudine:clinical and virological evaluations in HBe antigen-negative chronic hepatitis B. Aliment Pharmacol Ther 2004; 20: 2817.